Boron and Gadolinium Neutron Capture Therapy For Cancer Treatment

Hosmane, Narayan S.; Maguire, John A.; Zhu, Yongwei; Takagaki, Masao

doi:10.1142/9789814338684

Cited by 51 publications

(84 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In attempts to search for efficient cancer treatments, the boron neutron capture therapy (BNCT) has been widely explored in the last couple of decades as a binary targeting radiotherapeutic strategy . To realize its therapeutic efficacy, it is required to deliver a sufficient amount of boron selectively to the tumor lesion and irradiate neutron beam to the very site of tumor tissues and cells.…”

Section: Introductionmentioning

confidence: 99%

Highly Condensed Boron Cage Cluster Anions in 2D Carrier and Its Enhanced Antitumor Efficiency for Boron Neutron Capture Therapy

Choi

Jeon

Piao

2017

Adv Funct Materials

View full text Add to dashboard Cite

An attempt is made to apply layered double hydroxide (LDH) as a boron delivery carrier for boron neutron capture therapy (BNCT), which needs a sufficient amount of boron in tumor cells for its successful administration. To meet this requirement, a nanohybrid (BSH-LDH), mercaptoundecahydrocloso-dodecaborate (BSH) anionic molecules in LDH, is developed as a boron delivery system. The cellular boron content upon permeation of BSH-LDH nanoparticles (42.4 µg 10 B 10 −6 cells) in U87 glioblastoma cell line is found to be ≈2000 times larger than the minimum boron requirement (≈0.02 µg 10 B 10 −6 cells) for BNCT and also orders of magnitude higher than the previous results (0.2-1.5 µg 10 B 10 −6 cells) by those applied with other targeting strategies, and eventually results in excellent neutron capture efficiency even under such low dose (30 µg 10 B mL −1 ) and weak irradiation (1 × 10 12 n cm −2 corresponding to 20 min) condition. According to the biodistribution studies in xenograft mice model, the tumor-to-blood ratio of BSH in the BSH-LDH-treated-group is found to be 4.4-fold higher than that in the intact BSH treated one in 2 h after drug treatment. The present BNCT combined with boron delivery system provides a promising integrative therapeutic platform for cancer treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Highly Condensed Boron Cage Cluster Anions in 2D Carrier and Its Enhanced Antitumor Efficiency for Boron Neutron Capture Therapy

Choi

Jeon

Piao

2017

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…Icosahedral ortho-carboranes are important building blocks for the construction of boron compounds that have potential applications in broad areas of catalysis and also in medicine, including boron neutron capture therapy (BNCT). [19][20][21][22] They can be conveniently synthesized from decaborane (B 10 ). [39] Accordingly, the reaction of alkynes with the above boron precursors are usually carried out in an organic solvent such as toluene with typical yields of less than 75 % for the carborane products.…”

Section: Synthesis Of Ortho-carborane In Ionic Liquidsmentioning

confidence: 99%

“…[55][56][57] 10 B-enriched boron clusters are important building blocks to construct useful drug carriers for boron neutron capture therapy. [19,20] Currently, a 10 B-enriched decaborane (14) precursor has been synthesized in about 50 % yield from Na 10 BH 4 , which is prepared from the reduction of 10 B(OR) 3 from 10 B-enriched boric acid. [58] Na 10 BH 4 could be oxidized by I 2 to give Na[ 10 B 3 H 8 ]·3(C 4 H 8 O 2 ), which could then undergo oxidative cage fusion to produce 10 B 10 H 14 via 10 B 5 H 9 as an intermediate.…”

Section: Catalytic Isotope Exchange Reactions In Ionic Liquidsmentioning

confidence: 99%

“…[18] On the other hand, boron chemistry shows high diversity, and many potential applications such as boron neutron capture therapy for cancer treatment and efficient catalysts for olefin polymerization have emerged. [19][20][21][22] It has been repeatedly demonstrated that anionic icosahedral clusters, such as 1-carbacloso-dodecaborate [CB 11 H 12 ] -1 , are exceptionally stable toward oxidation and coordination reactions due to their unique molecular structures. [23] They neither contain lone pairs of electrons nor have nucleophilic centers.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ionic Liquids: Recent Advances and Applications in Boron Chemistry

Zhu

Hosmane

2017

Eur J Inorg Chem

Self Cite

View full text Add to dashboard Cite

Ionic liquids (ILs) are a type of low‐melting salts, which are generally nonvolatile, have low vapor pressure, very high boiling point, and excellent thermal stability. In addition, they have unique physical and chemical properties including highly variable viscosity, in contrast to common inorganic salts and organic liquids. Consequently, they have found potential applications in the broad area of green chemistry and as electrolytes. Recently, advances have been made in the use of ILs in boron chemistry, and as such various boron‐containing ILs have been reported and their applications in classic organic synthesis have been explored. Interestingly, many boron‐related reactions, such as hydroboration, were explored in ionic liquid media. This microreview mainly focuses on the progress of boron‐containing ILs and reactions involving boron compounds in ILs.

show abstract

“…The agents were developed as boron delivery agents for boron neutron capture therapy (BNCT) of brain tumors [11, 12]. Other types of carboranyl nucleoside derivatives were developed for the same and other purposes [13–17]. BNCT is a binary cancer treatment system that relies on the accumulation of boron-10 ( 10 B) in tumor cells followed by external neutron irradiation.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer

Agarwal

Khalil

Ishita

et al. 2015

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

A library of sixteen 2nd generation amino- and amido-substituted carboranyl pyrimidine nucleoside analogues, designed as substrates and inhibitors of thymidine kinase 1 (TK1) for potential use in boron neutron capture therapy (BNCT) of cancer, was synthesized and evaluated in enzyme kinetic-, enzyme inhibition-, metabolomic-, and biodistribution studies. One of these 2nd generation carboranyl pyrimidine nucleoside analogues (YB18A [3]), having an amino group directly attached to a meta-carborane cage tethered via ethylene spacer to the 3-position of thymidine, was approximately 3–4 times superior as a substrate and inhibitor of hTK1 than N5-2OH (2), a 1st generation carboranyl pyrimidine nucleoside analogue. Both 2 and 3 appeared to be 5′-monophosphorylated in TK1(+) RG2 cells, both in vitro and in vivo. Biodistribution studies in rats bearing intracerebral RG2 glioma resulted in selective tumor uptake of 3 with an intratumoral concentration that was approximately 4 times higher than that of 2. The obtained results significantly advance the understanding of the binding interactions between TK1 and carboranyl pyrimidine nucleoside analogues and will profoundly impact future design strategies for these agents.

show abstract

Boron and Gadolinium Neutron Capture Therapy For Cancer Treatment

Cited by 51 publications

References 0 publications

Highly Condensed Boron Cage Cluster Anions in 2D Carrier and Its Enhanced Antitumor Efficiency for Boron Neutron Capture Therapy

Highly Condensed Boron Cage Cluster Anions in 2D Carrier and Its Enhanced Antitumor Efficiency for Boron Neutron Capture Therapy

Ionic Liquids: Recent Advances and Applications in Boron Chemistry

Synthesis and evaluation of thymidine kinase 1-targeting carboranyl pyrimidine nucleoside analogs for boron neutron capture therapy of cancer

Contact Info

Product

Resources

About